Cargando…

Interferon gene therapy with nadofaragene firadenovec for bladder cancer: from bench to approval

Bladder cancer is a prevalent malignancy with limited therapeutic options, particularly for patients who are unresponsive to Bacillus Calmette-Guérin (BCG). The approval of interferon-α (IFNα) gene therapy with nadofaragene firadenovec (Adstiladrin(®)), the first gene therapy for genitourinary malig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martini, Alberto, Tholomier, Côme, Mokkapati, Sharada, Dinney, Colin P. N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495564/ https://www.ncbi.nlm.nih.gov/pubmed/37705979 http://dx.doi.org/10.3389/fimmu.2023.1260498

Ejemplares similares

Nadofaragene Firadenovec: First Approval
por: Lee, Arnold
Publicado: (2023)

Correction to: Nadofaragene Firadenovec: First Approval
por: Lee, Arnold
Publicado: (2023)

The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Beinfeld, Molly, et al.
Publicado: (2021)

Lentiviral interferon: A novel method for gene therapy in bladder cancer
por: Mokkapati, Sharada, et al.
Publicado: (2022)

Bladder-sparing protocols in the treatment of muscle-invasive bladder cancer
por: Tholomier, Côme, et al.
Publicado: (2020)

Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activation
por: Plote, Devin, et al.
Publicado: (2019)

From bench to bedside: the history and progress of CAR T cell therapy
por: Mitra, Aroshi, et al.
Publicado: (2023)

Interferon and interferon-stimulated genes in HBV treatment
por: Li, Qirong, et al.
Publicado: (2022)

Genetic Variants in Telomere-Maintenance Genes and Bladder Cancer Risk
por: Chang, Joshua, et al.
Publicado: (2012)

Therapeutic Potential of Gene-Modified Regulatory T Cells: From Bench to Bedside
por: Chae, Wook-Jin, et al.
Publicado: (2018)

CXCR2: From Bench to Bedside
por: Stadtmann, Anika, et al.
Publicado: (2012)

Has retinal gene therapy come of age? From bench to bedside and back to bench
por: Trapani, Ivana, et al.
Publicado: (2019)

Biliary mucinous cystic neoplasm mimicking a hydatid cyst: a case report and literature review
por: Tholomier, Côme, et al.
Publicado: (2019)

Models and Tools for Investigating Eosinophilic Esophagitis at the Bench
por: Uchida, Amiko M., et al.
Publicado: (2022)

Immunological Aspects of Approved MS Therapeutics
por: Rommer, Paulus S., et al.
Publicado: (2019)

Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer
por: Jayaratna, Isuru S., et al.
Publicado: (2015)

Next-Generation Anti-Angiogenic Therapies as a Future Prospect for Glioma Immunotherapy; From Bench to Bedside
por: Shamshiripour, Parisa, et al.
Publicado: (2022)

Bench, Bedside, Toolbox: T-Cells Deliver on Every Level
por: Laugel, Bruno
Publicado: (2014)

Natural Killer Cell Immunotherapy: From Bench to Bedside
por: Domogala, Anna, et al.
Publicado: (2015)

Externally-Controlled Systems for Immunotherapy: From Bench to Bedside
por: Tristán-Manzano, María, et al.
Publicado: (2020)

Investigating population-level immunosenescence: From bench to bedside
por: Cunha, Lucas Leite, et al.
Publicado: (2022)

Evolution of Interferons and Interferon Receptors
por: Secombes, Chris J., et al.
Publicado: (2017)

Interferons in Sjögren’s Syndrome: Genes, Mechanisms, and Effects
por: Li, He, et al.
Publicado: (2013)

Intrinsic subtypes and bladder cancer metastasis
por: McConkey, David J., et al.
Publicado: (2016)

Phage Display Derived Monoclonal Antibodies: From Bench to Bedside
por: Alfaleh, Mohamed A., et al.
Publicado: (2020)

Non-coding RNAs in Rheumatoid Arthritis: From Bench to Bedside
por: Wang, Jinghua, et al.
Publicado: (2020)

Dendritic cell vaccine of gliomas: challenges from bench to bed
por: Zheng, Ye, et al.
Publicado: (2023)

Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval?
por: Brancati, Serena, et al.
Publicado: (2021)

Interferon Genes Are Influenced by 17β-Estradiol in SLE
por: Singh, Ram P., et al.
Publicado: (2021)

The Significance of Interferon-γ in HIV-1 Pathogenesis, Therapy, and Prophylaxis
por: Roff, Shannon R., et al.
Publicado: (2014)

Interferon therapy and its association with depressive disorders – A review
por: Lai, Jing Yung, et al.
Publicado: (2023)

Immune Responses to AAV-Vectors, the Glybera Example from Bench to Bedside
por: Ferreira, Valerie, et al.
Publicado: (2014)

Insights into the Role of Helicobacter pylori Infection in Preeclampsia: From the Bench to the Bedside
por: Tersigni, Chiara, et al.
Publicado: (2014)

Monomeric C-Reactive Protein and Cerebral Hemorrhage: From Bench to Bedside
por: Di Napoli, Mario, et al.
Publicado: (2018)

Combinatorial Herpes Simplex Vaccine Strategies: From Bedside to Bench and Back
por: Chentoufi, Aziz A., et al.
Publicado: (2022)

The paradoxical role of MDSCs in inflammatory bowel diseases: From bench to bedside
por: Zhao, Fan, et al.
Publicado: (2022)

Targeting 4-1BB for tumor immunotherapy from bench to bedside
por: Wang, Ya-Tao, et al.
Publicado: (2022)

Efficacy evaluation of multi-immunotherapy in ovarian cancer: From bench to bed
por: Hu, Xiaoyi, et al.
Publicado: (2022)

Interferon add-on therapy increased clinical cure significantly for interferon-experienced chronic hepatitis B patients with low HBsAg
por: Yang, Xiaoan, et al.
Publicado: (2022)

Advances of mesenchymal stem cells and their derived extracellular vesicles as a promising therapy for acute respiratory distress syndrome: from bench to clinic
por: Zhuang, Xiaoli, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_opgdgieih1bi79v2uj7a7n1vjp